CoChat

Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials

Open access
Wilens, Timothy E., Gault, Laura M., Childress, Ann, Kratochvil, Christopher J., Bensman, Lindsey, Hall, Coleen M., Olson, Evelyn, Robieson, Weining Z., Garimella, Tushar S., Abi-Saab, Walid M., Apostol, George, Saltarelli, Mario D. · 2011 · Journal of the American Academy of Child & Adolescent Psychiatry
Cited by 34

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective To assess the safety and efficacy of ABT-089, a novel α4β2 neuronal nicotinic receptor partial agonist, vs. placebo in children with attention-deficit/hyperactivity disorder (ADHD). Method Two multicenter, randomized, double-blind, placebo-controlled, parallel-group studies of children 6–12 years old were conducted. Study 1 (n=274) assessed six treatment groups over 8 weeks: 4 once-daily (QD) ABT-089 doses (0.085–0.700 mg/kg), QD atomoxetine, and placebo.Study 2 (n=119) assessed three treatment groups over 6 weeks: 2 QD ABT-089 doses (0.7 mg/kg, 1.4 mg/kg) and placebo. The primary efficacy variable was the investigator-administered ADHD Rating Scale-IV: Home Version (ADHD-RS-IV [HV]) Total Score. Safety was assessed by adverse event (AE) monitoring, lab tests, vital signs, physical exams, and electrocardiogram measures. Results There was no statistically significant difference between ABT-089 and placebo in mean change from baseline to final evaluation of ADHD-RS-IV (HV) Total Score or other outcome measures at any dose in either study; in Study 1, atomoxetine showed statistically significant improvement for the primary and most secondary endpoints. ABT-089 was generally safe and well tolerated, with no statistically significant difference between any ABT-089 dose and placebo in the overall incidence of any specific AE, and no clinically significant changes in other safety measures. Conclusions ABT-089 did not show efficacy on the primary efficacy variable, the ADHD-RS-IV (HV) Total Score, or other measures of ADHD symptomatology in children with ADHD, and had a safety profile similar to placebo. These results contrast with published reports of efficacy of nicotinic modulators in adults with ADHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2010.10.001

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 34

Metadata

Authors
Wilens, T. E., Gault, L. M., Childress, A., Kratochvil, C. J., Bensman, L., Hall, C. M., Olson, E., Robieson, W. Z., Garimella, T. S., Abi-Saab, W. M., Apostol, G., & Saltarelli, M. D.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2011-01
Volume
50
Issue
1
Pages
73-84.e1
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2048740041
Cited by
34
References
15
FWCI
3.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. https://app.cochat.ai/papers/10.1016/j.jaac.2010.10.001
The paper
Wilens, T. E., Gault, L. M., Childress, A., Kratochvil, C. J., Bensman, L., Hall, C. M., Olson, E., Robieson, W. Z., Garimella, T. S., Abi-Saab, W. M., Apostol, G., & Saltarelli, M. D. (2011). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2010.10.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.